[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,797,0,25,[9,41,70,95,123,143,173,201,230,257,286,306,336,360,380,404,423,446,474,502,524,581,598,641,656],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100652971","three-dimensional-molds-based-on-radiological-images-in-patients-with-cancer-the-direct-trial-100652971",false,"NCT07778173","Three-Dimensional Molds Based on Radiological imagEs in Patients With Cancer: the DIRECT Trial","DIRECT","Inclusion Criteria:\n\nTo be eligible for the study, the study candidate must:\n\n* be willing and able to give informed consent and give their written consent for the participation in the study (in case of a child (\\\u003C15-year-old), the consent is collected in an age-appropriate manner from the study candidate and their legal guardian(s))\n* have a malignant or likely malignant tumor\u002Ftumors and undergo a surgical operation.\n\nExclusion Criteria:\n\nTo be eligible for the study, the study candidate cannot:\n\n* lack the capacity to provide informed consent (if a legal guardian objects to the participation of their child (\\\u003C15-year-old), the child is not eligible);\n* be at risk of having their standard of care treatment jeopardized by the study, in the opinion of their physician.","ALL",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Determination of the sites from which the histopathological samples in surgically removed lesions are collected is still done by eye by a pathologist. As radiological determination of regions of interest has already proven useful in in vivo use cases, the implementation of sampling of ex vivo lesions with the help of radiological imaging suggests great potential. By developing and implementing mold printing processes, these molds have the potential to vastly improve the accuracy and consistency of histopathological sampling and collection of tissue samples from different regions of tumor, leading to improved characterization, more individualized treatments, and eventually better survival.",[26,27],"Cancer","Tumor","RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":32},"2024-05-31",{"date":36,"type":20},"2033-12-15",{"name":38,"class":39},"Tampere University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100646693","rescue-a-workplace-dietary-intervention-for-uk-firefighters-100646693","NCT07687849","Dietary Patterns Following a Firefighter Nutrition Education Programme","Assessing Dietary Patterns and the Longer-term Impact of a Firefighter Nutrition Education Programme (RESCUE)","RESCUE","Inclusion Criteria:\n\nWholetime (full-time) operational firefighters employed by Avon Fire \\& Rescue Service.\n\nAged 18 years or over. Able to provide informed consent.\n\nExclusion Criteria:\n\nIndividuals who are not full-time operational firefighters within Avon Fire and Rescue service (e.g. administrative staff, support roles, or part-time on-call firefighters, firefighters from other fire services)",true,"18 Years",{"count":52,"type":20},350,"OBSERVATIONAL","Firefighters may be at increased risk of poor dietary habits due to nature of shift work, extended duty periods, and reliance on food available within fire station environments. Irregular working patterns and limited access to healthy food options during shifts can contribute to poorer dietary intake. Previous research suggests that occupational environments and works schedules can significantly influence food choices and overall nutrition in emergency service personnel.\n\nThis study is being conducted to assess current dietary behaviours among firefighters and to evaluate changes following implementation of the RESCUE (Resilient Eating Strategies for Cancer-Risk in Uniformed Emergency workers) nutrition education programme, a structured programme designed to improve dietary knowledge and food choices. It will also explore the influence of station-based food provision on dietary intake.\n\nThe research is important as firefighters face increased occupational health risks, including elevated cancer risk, where diet may play a role in long-term health outcomes. Improving dietary habits in this group may improve health, occupational performance, and reduce the risk of chronic disease. The findings will provide evidence to inform the development of practical, targeted nutrition interventions within fire and rescue services.",[26,56],"Diet Habits",[58,59,26,60,61],"Firefighter","Diet","Inflammation","Education",{"date":31,"type":32},{"date":64,"type":32},"2026-05-05",{"date":66,"type":20},"2027-07",{"name":68,"class":69},"Avon Fire and Rescue Service","OTHER_GOV",{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":40},"100531693","construction-and-clinical-translation-of-ace-targeted-nuclear-medicine-imaging-probe-100531693","NCT06203119","Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe","Inclusion Criteria\n\n1. Age 18 to 75 years, inclusive; sex unrestricted.\n2. Patients with triple-negative breast cancer (TNBC) or suspected TNBC who are scheduled to undergo pathological tissue biopsy or surgical treatment for the tumor in the near future (within 2 months).\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. Estimated life expectancy of ≥12 weeks.\n5. Adequate hematologic, coagulation, hepatic, and renal function, defined as follows:\n\nWBC ≥4.0 × 10⁹\u002FL or neutrophil count ≥1.5 × 10⁹\u002FL; PLT ≥100 × 10⁹\u002FL; Hb ≥90 g\u002FL; PT or APTT ≤1.5 × the upper limit of normal (ULN); Total bilirubin ≤1.5 × ULN; ALT and AST ≤2.5 × ULN, or ≤5 × ULN in patients with liver metastases; ALP ≤2.5 × ULN, or ≤4.5 × ULN in patients with bone or liver metastases; BUN ≤1.5 × ULN; Serum creatinine ≤1.5 × ULN. 6:Presence of at least one measurable target lesion according to RECIST version 1.1.\n\n7::Female participants must use effective contraceptive measures during the study period and for 6 months after completion of the study. Male participants must agree to use effective contraceptive measures during the study period and for 6 months after completion of the study.\n\n8:Ability to understand the study procedures, voluntarily sign the informed consent form (ICF), and demonstrate good compliance with study requirements.\n\n9:Baseline assessment established based on \\^18F-FDG PET\u002FCT findings. Exclusion Criteria\n\n1. Presence of any of the following conditions: brain metastases, except asymptomatic primary or metastatic brain tumors that do not require treatment; carcinomatous meningitis; myocardial infarction within 6 months prior to enrollment; unstable angina; high risk of uncontrolled arrhythmia; history of coronary artery bypass grafting; cerebrovascular accident within 6 months prior to enrollment; congestive heart failure (NYHA Class III-IV); pulmonary embolism; deep vein thrombosis; concurrent infection requiring intravenous antibiotic treatment within the previous 2 weeks; or receipt of immunosuppressive therapy following organ transplantation.\n2. Primary central nervous system tumors.\n3. HBV DNA ≥10⁴ copies\u002FmL or ≥2,000 IU\u002FmL.\n4. HCV RNA ≥1,000 copies\u002FmL.\n5. Positive HIV antibody or syphilis antibody test.\n6. History of acute or subacute intestinal obstruction or inflammatory bowel disease.\n7. Pregnancy, breastfeeding, or plans to become pregnant during the study period.\n8. Known allergy to the investigational drug or any of its excipients.\n9. History of substance abuse involving psychiatric medications that cannot be discontinued, or presence of a psychiatric disorder.\n10. Inability to lie flat for at least 30 minutes.\n11. Known allergy to any component of the imaging agents or antibodies used in the study.\n12. Inability to undergo PET\u002FCT imaging.\n13. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.","75 Years",{"count":78,"type":20},20,[80],"PHASE1","This prospective, single-center, open-label study aims to evaluate the safety, biodistribution, and tumor imaging characteristics of the novel ACE1-targeted PET radiotracer 68Ga-DOTA-BPP in patients with confirmed or suspected triple-negative breast cancer (TNBC). Participants will undergo \\^68Ga-DOTA-BPP PET\u002FCT and 18F-FDG PET\u002FCT. Visual and semiquantitative imaging analyses will be performed to assess tracer uptake in tumor lesions and normal organs. The relationship between \\^68Ga-DOTA-BPP uptake and ACE1 expression will also be explored in participants with available tumor tissue.",[26],[84,85,86,87],"PET\u002FCT","TNBC","68Ga labeling","diagnosis",{"date":31,"type":32},{"date":90,"type":32},"2024-03-06",{"date":92,"type":20},"2026-12-02",{"name":94,"class":39},"Peking University Cancer Hospital & Institute",{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":40},"100652148","effect-of-pecha-kucha-based-education-on-symptom-management-and-quality-of-life-in-patients-receiving-chemotherapy-100652148","NCT07769931","Effect of Pecha Kucha-Based Education on Symptom Management and Quality of Life in Patients Receiving Chemotherapy","The Effect of Education Provided Using the PechaKucha Method on Symptom Management and Quality of Life in Patients Receiving Chemotherapy","Inclusion Criteria:\n\n* Willing to participate in the study.\n* Currently receiving treatment in the chemotherapy unit.\n* Aged 18 years or older, willing to participate, and able to communicate effectively.\n\nExclusion Criteria:\n\n* Being under 18 years of age.\n* Having cognitive or communication difficulties.\n* Having a visual or hearing impairment.\n* Being in an advanced or terminal stage of the disease.\n* Having a physical or psychological condition that prevents active participation in the educational process.",{"count":103,"type":20},140,[23],"This randomized controlled study aims to evaluate the effect of education delivered using the PechaKucha method on symptom management and quality of life in patients receiving chemotherapy. Participants will be randomly assigned to either an intervention group or a control group.\n\nParticipants in the intervention group will receive individual education on symptom management during chemotherapy using the PechaKucha method. The education will be delivered as a video presentation consisting of 20 visual slides and lasting 6 minutes and 40 seconds. Participants in the control group will receive routine\u002Fstandard patient education.\n\nSymptom severity and quality of life will be assessed before the education and one week after the intervention using the Edmonton Symptom Assessment System (ESAS) and the EQ-5D. The study will compare changes in symptom severity and quality of life between the intervention and control groups to determine whether PechaKucha-based education is effective in supporting symptom management and quality of life among patients receiving chemotherapy.",[26,107],"Neoplams",[109,110,111,112,113,114],"cemoteraphy","PechaKucha","Patient Education","Symptom Management","Quality of Life","Oncology Nursing","2026-08-19",{"date":29,"type":32},{"date":118,"type":32},"2026-06-03",{"date":120,"type":20},"2026-10",{"name":122,"class":39},"Istanbul Aydın University",{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":40},"100651984","characterization-of-skin-changes-clinical-physiological-and-pathological-from-the-use-of-moisturizers-in-participants-with-cancer-experiencing-dermatological-adverse-events-100651984","NCT07767448","Characterization of Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events","Characterization of Skin Changes (Clinical, Physiological and Pathological) Leading to Dermatological Adverse Events From Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Adult patient (18 years or older).\n* Patients diagnosed with cancer.\n* Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and\u002For immune checkpoint inhibitors).\n* Patient experiencing a dermatological adverse event from a cancer treatment or therapy.\n\nExclusion Criteria:\n\n* Patient is unable to understand scope of the study.\n* Patient is unable to provide written informed consent.\n* Patient is healthy.",{"count":131,"type":20},50,[23],"The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:\n\nDoes cosmeceutical topical moisturizers help with skin dryness?\n\nParticipants will:\n\n* Visit the clinic for a baseline visit to complete skin evaluation and tests.\n* Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.\n* Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.",[26],"NOT_YET_RECRUITING",{"date":31,"type":32},{"date":138,"type":20},"2026-08",{"date":140,"type":20},"2029-02",{"name":142,"class":39},"Stanford University",{"id":144,"slug":145,"hasResults":12,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":49,"sex":17,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":172},"100409252","connect-for-cancer-prevention-study-connect-100409252","NCT04609072","Connect for Cancer Prevention Study (Connect)","Connect for Cancer Prevention Study: A Prospective Cohort Study Within Integrated Healthcare Systems in the US","* INCLUSION CRITERIA:\n\nDue to the minimal risk nature of this protocol, all individuals interested and able to participate in Connect for Cancer Prevention, who meet the eligibility criteria at time of initial study invitation, will be able to participate. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Patients or members of participating IHCS at the time of enrollment\n* Age between 30 and 70 years old at study invitation\n\nIf an individual is determined to be ineligible at the time of enrollment due to age, the individual will be allowed to re-enroll at a later time once the recruit meets the age requirement. This includes recruits that did not meet the original age requirement of 40-65 years of age but now meet the updated age range of 30-70.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria at time of initial study invitation will be excluded from participation in this study:\n\n* Individuals with a confirmed history of invasive cancer (other than non-melanoma skin cancer)\n* Individuals with known cognitive impairment documented in their medical record","30 Years","70 Years",{"count":153,"type":20},200000,"Background:\n\nThe National Cancer Institute, part of the National Institutes of Health, has partnered with nine health care systems across the U.S. to establish the Connect for Cancer Prevention Study. While researchers have made important discoveries, there is more to learn to lower the number of people affected by cancer. By taking part in Connect, participants can help researchers learn how the way we live, our genetics, and our health history may affect cancer risk.\n\nObjective:\n\nTo study and better understand the causes of cancer and to find new ways to prevent it.\n\nEligibility:\n\nThe study will include 200,000 adults who get their health care from a partner health care system, are between 30 and 70 years old at enrollment, and have never had cancer. People remain eligible to join if they have or once had non-melanoma skin cancer, or a condition that may raise cancer risk (such as ductal carcinoma in situ, or DCIS).\n\nDesign:\n\nEligible recruits can sign up for Connect online by creating an account on MyConnect using their email address or phone number. After creating an account, they will complete the informed consent process. All information shared through MyConnect is secure to protect participant privacy. After joining the study, participants will be asked to answer online health surveys a few times a year, donate samples of blood, urine, and saliva every two to three years, and safely share access to their electronic health records with Connect. In the future, participants may donate unused samples that are collected at clinical visits, like tissue, stool, or blood, and may mail in samples collected at home. Participants may also share information from personal health trackers, like wearable devices or apps.\n\nThis information will help researchers study the health and behavior patterns that may affect cancer risk.\n\nIt takes time to understand the causes of cancer, so Connect will go on for many years. The longer people participate, the more researchers may learn. Participants can leave the study at any time.\n\nLearn more about Connect by visiting cancer.gov\u002Fconnectstudy.",[26,156],"General Research Use",[158,159,160,161,162,163],"Risk Factors","medical conditions","Pathology","Blood","Urine","Natural History",{"date":29,"type":32},{"date":166,"type":32},"2021-07-26",{"date":168,"type":20},"2070-12-31",{"name":170,"class":171},"National Cancer Institute (NCI)","NIH",10,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":189,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":40},"100649992","feasibility-and-acceptability-of-empowered-relief-for-american-indians-with-pain-during-and-after-cancer-treatment-100649992","NCT07742449","Feasibility and Acceptability of Empowered Relief for American Indians With Pain During and After Cancer Treatment","ejames3","Inclusion Criteria:\n\n* Identifies as American Indian\n* Has history of a cancer diagnosis\n* Is currently undergoing or has completed active cancer treatment\n* Experiences body pain most or every day\n* Pain duration at least 3 months\n* English fluency\n\nExclusion Criteria:\n\n* Significant psychological and cognitive impairment that limits one's ability to complete study tasks (completion of online survey, attending the Zoom-based ER class)\n* Life-threatening acute illness (e.g., infection, heart attack, injury)\n* No access to a computer, a smartphone, or a tablet",{"count":181,"type":20},70,[23],"This project will evaluate the feasibility and acceptability of Empowered Relief (ER) among American Indian adults who are currently receiving or have completed active cancer treatments at Stephenson Cancer Center (SCC). ER is a single-session, Zoom-based, 2-hour, skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily practice. ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety at 3 and 6 months post-treatment. Because of its brief, didactic nature and Zoom delivery, ER can accommodate large class sizes and may address accessibility disparities among underserved cancer populations. While ER is being studied across various non-cancer populations and has been adopted as standard of care in leading healthcare institutions in the U.S. and abroad, it has not been tested in American Indians with cancer.",[26,185,186,187,188],"Pain","Pain Management","Chronic Pain","American Indian or Alaska Native",[26,190,185,187,191,192],"Cancer Survivor","Native American","American Indian","2026-08-18",{"date":29,"type":32},{"date":196,"type":20},"2026-08-01",{"date":198,"type":20},"2027-12",{"name":200,"class":39},"University of Oklahoma",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":40},"100565662","feasibility-of-intermittent-fasting-during-chemotherapy-100565662","NCT06645093","Feasibility of Intermittent Fasting During Chemotherapy","Intermittent Fasting During Curatively Intended Chemotherapy for Malignant Lymphoma - a Randomized Feasibility Trial","FasteStudien","Inclusion Criteria:\n\n* Patients diagnosed with diffuse large B-cell lymphoma planned to receive R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisolone) and Hodgkin lymphoma receiving ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)\n* Age ≥ 18 years\n* ECOG status 0-2\n* Normal weight and overweight (BMI ≥ 18,5 kg\u002Fm\\^2)\n\nExclusion Criteria:\n\n* Receiving concurrent radiation therapy and\u002For treatment\n* Other concomitant disease that may make intermittent fasting complicated such as diabetes mellitus\n* ECOG status: \\> 3\n* BMI \\\u003C 18,5 kg\u002Fm2\n* Age \\> 80 years","80 Years",{"count":211,"type":20},40,[23],"The goal of this randomized controlled parallel group trial is to examine if fasting before and after chemotherapy is safe, feasible and acceptable. The study population will include patients with either Hodgkin lymphoma or Diffuse Large B Cell Lymphoma.\n\nThe main questions aimed to answer are:\n\nWhether fasting during chemotherapy is safe for patients, whether it is feasible to implement in a clinical setting, and whether patients find it acceptable.\n\nWe also want to examine a number of patient-reported outcome measures regarding health status and quality of life, such as dietary intake and adverse events from chemotherapy.\n\nResearchers will compare fasting to standard treatment.\n\nParticipants will:\n\n* Fast 24 hours before and 24 hours after chemotherapy in addition to standard treatment or receive only standard treatment\n* Keep a diary of their dietary intake 24 hours before and 24 hours after chemotherapy\n* Keep a diary of their dietary intake for three consecutive days between chemotherapy cycles\n* Answer questionnaires\u002Fquestions in relation to side effects from fasting, side effects\u002Fadverse events of chemotherapy, quality of life\n* Take bioimpedance analysis (including body mass index and body composition)\n* Take blood- and feces samples",[215,26,216],"Lymphoma","Fasting",[218,219,220,221,222,216],"Chemotherapeutic Toxicity","Chemotherapy","Adverse Effect","Short-term fasting","Feasibility studies",{"date":29,"type":32},{"date":225,"type":32},"2024-10-31",{"date":227,"type":20},"2026-12",{"name":229,"class":39},"University of Oslo",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":49,"sex":17,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":240,"conditions":241,"keywords":246,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":40},"100469897","a-natural-history-study-of-metabolic-sizing-in-health-and-disease-100469897","NCT05398783","A Natural History Study of Metabolic Sizing in Health and Disease","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all the following criteria for their cohort:\n\nCohort 1 - Healthy Volunteers\n\n* Male or female, aged \\>=2 years\n* In good general health as evidenced by medical history\n\nCohort 2 - Patients\n\n* Male or female, aged \\>=2 years\n* Diagnosed with diseases thought to alter metabolism or body composition (such as weight loss or gain, diabetes, renal disease, obesity, cancer, etc.) or taking medications thought to alter metabolism or body composition.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Participants over 200 kg due to the weight limit of the equipment.\n* Presence of any implanted device that would interfere with measurements.\n* Any moderate to severe limitations in mobility that would impede participation\n* Hemoglobin less than 10 g\u002FdL (in participants who would have blood drawn for research purposes).\n* Participants with dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals.\n* Participants unwilling or unable to give informed consent.\n* Participants with any other significant physical, medical, or psychiatric limitations, illness or conditions that may preclude them from completing the majority of the tests in this study per the discretion of the PI.","2 Years","99 Years",{"count":239,"type":20},2000,"Background:\n\nScientists have long used simple measures (such as height and weight) to estimate how much a person s body uses food (calories) as energy, as commonly called the metabolic rate. But metabolism varies among people with similar body sizes. Scientists now believe the old formulas for estimating metabolic rates may not work well for all people. Researchers want to find more accurate ways to measure a person s metabolism.\n\nObjective:\n\nThis natural history study will examine the relationships between metabolism, body composition, and body surface area in a wide range of people.\n\nEligibility:\n\nHealthy children and adults aged 2 years or older. Also, people aged 2 years or older with conditions that may alter metabolism. These may include diabetes, obesity, renal disease, or cancer.\n\nDesign:\n\nParticipants will spend 2 days and 1 night in the hospital. They will provide a medical history and answer questions about their activity levels, the foods they eat, and their lifestyle. They will also eat a special diet.\n\nParticipants will undergo many tests:\n\nThey will lie in a bed with a clear hood covering their head for 30 to 45 minutes to measure the gases in their breath.\n\nThey will lie on a padded table for about 15 minutes while their body is scanned.\n\nThey will stand on a platform while a 3D scanner measures their body.\n\nThey will have a test to measure how fast an electric signal moves through their body.\n\nThey will grip an instrument to measure the strength of their hands.\n\nThey will drink salty water and provide blood and urine samples.\n\nParticipants may be invited to return for these 2-day visits up to 8 times per year. Return visits must be at least 2 weeks apart.",[242,26,243,244,245],"Metabolic Disorders","Chronic Kidney Disease","Diabetes","Normal Physiology",[247,248,249,163],"Body Composition","Metabolism","Body Surface Area",{"date":115,"type":32},{"date":252,"type":32},"2022-10-25",{"date":254,"type":20},"2031-07-01",{"name":256,"class":171},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100465071","phase-3-abatacept-in-immune-checkpoint-inhibitor-myocarditis-100465071","NCT05335928","Abatacept in Immune Checkpoint Inhibitor Myocarditis","AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis","ATRIUM","Inclusion Criteria:\n\n1. Must have provided informed consent in a manner approved by the Investigator's Institutional Review Board (IRB) prior to any study-related procedure being performed. If a participant is unable to provide informed consent due to his\u002Fher medical condition, the participant's legally authorized representative may consent on behalf of the study participant, as permitted by local law and institutional Standard Operating Procedures;\n2. Aged greater than or equal to 18 years at the time of informed consent;\n3. Recent use of an FDA-approved immune checkpoint inhibitor (ICI, defined as administered an immune checkpoint inhibitor ≤ 6 months of myocarditis diagnosis), alone or in combination with other cancer therapies (i.e. chemotherapy, radiation therapy or targeted therapy). The FDA-approved ICI could be given as part of a clinical trial but not in combination with a new investigational agent which may cause myocarditis;\n4. A diagnosis of myocarditis.\n5. Hospitalized at the time of randomization;\n6. On 1000 mg of solumedrol per day for myocarditis or with an intent to initiate 1000 mg of solumedrol per day for myocarditis within 24 hours of first administration of study drug;\n7. Serum evidence of ongoing myocardial injury: Serum evidence of ongoing myocardial injury will be defined as an institutional troponin (either conventional or high-sensitivity troponin I or T, using the standard institutional assay) with a value that is ≥5 times the upper limit of the reference standard normal for that institution. The troponin assay may be adjusted based on sex depending on institutional standards. This value of troponin of ≥5 times above the institutional upper limits of normal value must be noted within 10 days prior to potential randomization. The 10-day period can be in the outpatient or inpatient setting. For example, a participant with a troponin value that on one occasion was ≥5 times the upper limits of institutional normal in the 10-day window prior to potential randomization (whether in the inpatient or outpatient setting), but later decreases below that threshold, typically due to starting corticosteroids, would still be considered eligible;\n8. The following laboratory parameters, not older than 48 hours at the time of randomization, and measured as part of usual care:\n\n   * Total white blood cell (WBC) count \\>2,500\u002Fμl\n   * Absolute neutrophil count (ANC) \\>1,500\u002FμL\n   * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\\u003C20 times the upper limit of the institutional normal ranges;\n9. Women of childbearing potential (i.e., not postmenopausal, or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test prior to randomization. Participating women of childbearing potential must be willing to consistently use effective methods of contraception from screening until at least 90 days after administration of the last dose of study drug. Participating men must also be willing to consistently use effective methods of contraception from screening until at least 90 days after administration of the last dose of study drug; and\n10. Must be willing and able to abide by all study requirements and restrictions.\n\nExclusion Criteria:\n\n1. Must not have experienced any of the following (as defined in the section on the primary endpoint) in the 30-day period prior to randomization:\n\n   * A sudden cardiac arrest\n   * Cardiogenic shock as defined. A significant bradyarrhythmia (Mobitz type II second degree atrioventricular block or third degree (complete) atrio-ventricular (AV) block, for which an intervention with a temporary or permanent pacemaker is completed or recommended).\n   * A significant tachyarrhythmia (ventricular fibrillation of any duration or sustained ventricular tachycardia (\\>30 seconds, \\>120 beats per minute); or a ventricular tachyarrhythmia requiring intervention.\n2. Recent (≤2 month) exposure to abatacept or belatacept.\n3. Concurrent or recent (≤2 month) use of the following non-corticosteroid immunosuppressive therapies prior to randomization: mycophenolate, JAK STAT inhibitors (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib), tacrolimus, anti-thymocyte globulin, alemtuzumab, infliximab, and plasma exchange. The use of intravenous immunoglobulin is permitted prior to randomization and during study treatment.\n4. Currently enrolled in another interventional study utilizing systemic agents for the management of ICI-related toxicities.\n5. Female who is pregnant, breastfeeding, or is considering becoming pregnant during the study or for approximately 90 days after the last dose of study drug.\n6. Male who is considering fathering a child or donating sperm during the study or for approximately 30 days after the last dose of study drug.\n7. Any active, chronic, or recurrent viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study. These may include hepatitis B virus (HBV) or hepatitis C virus (HCV), recurrent or disseminated (even a single episode) herpes zoster, and disseminated (even a single episode) herpes simplex. Active HBV and HCV are defined as: HBV: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for Hepatitis B core antibody (HBc Ab) positive (+) participants; HCV: HCV ribonucleic acid (RNA) detectable in any participant with anti-HCV antibody (HCV Ab). Patients with active Covid-19 infection will be excluded. This is defined as the period of ongoing symptoms in the setting of a positive Covid-19 test, or until 10 days after symptom onset and after resolution of fever for at least 24 hours, without the use of fever-reducing medications.\n8. Known active tuberculosis (TB), history of incompletely treated TB, suspected or known extrapulmonary TB, suspected or known systemic bacterial or fungal infections;\n9. Receipt of any live vaccine within four weeks prior to the first dose of study drug, or expected need of live vaccination during study participation including at least 90 days after the last dose of IV study drug.\n10. Any medical condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would, in the opinion of the Investigator, increase the risk of the participant by participating in the study.\n11. Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments.",{"count":266,"type":20},390,[268],"PHASE3","The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.",[271,26],"Myocarditis Acute",[273,274,275,276,277],"Immune checkpoint Inhibitor","Myocarditis","Abatacept","Immune therapy","Immune related adverse events",{"date":29,"type":32},{"date":280,"type":32},"2022-07-02",{"date":282,"type":20},"2029-10-09",{"name":284,"class":39},"Massachusetts General Hospital",31,{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":40},"100652682","efficacy-of-an-inpatient-yoga-therapy-program-for-cancer-patients-100652682","NCT07776587","Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients","Efficacy Of An Inpatient Yoga Therapy Program For Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Male and female cancer patients\n2. Age 18 or older\n3. Understand and read English\n4. Scheduled to undergo their first autologous or allogeneic HSCT (even number of each) at MDA with a minimum of 2-week inpatient hospital stay\n5. Be willing to follow protocol requirements\n6. Sign a written informed consent\n\nExclusion Criteria:\n\n1. Have extreme mobility issues that preclude participating in the Yoga program\n2. Have major thought disorders such as schizophrenia or uncontrolled bipolar disorder\n3. Have hematopoietic cell transplantation HCT comorbidity score of 3 or higher (excluding cancer)",{"count":294,"type":20},300,[23],"The purpose of this study is to learn whether a yoga therapy program can improve quality of life and reduce symptoms in people undergoing stem cell transplantation compared with an enhanced standard care physical activity program.",[26],"2026-08-17",{"date":29,"type":32},{"date":301,"type":20},"2027-02-01",{"date":303,"type":20},"2032-04-13",{"name":305,"class":39},"M.D. Anderson Cancer Center",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":21,"phases":314,"briefSummary":315,"conditions":316,"keywords":322,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":40},"100652655","monitoring-for-cardiotoxicity-using-wearable-devices-while-undergoing-cancer-treatments-mct-wave-100652655","NCT07776964","Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE)","Inclusion Criteria:\n\n* Diagnosis of breast cancer, hematologic malignancy including leukemia or lymphoma, or multiple myeloma\n* At least 18 years of age\n* Capable of understanding and willing to sign a consent form for this study\n\nExclusion Criteria:\n\n* Known allergy to adhesive patches used for ambulatory EKG monitoring\n* Children\n* Cognitively challenged individuals\n* Prisoners\n* Active service military personnel",{"count":313,"type":20},72,[23],"This pilot study will evaluate the validity and feasibility of ambulatory cardiac monitoring to identify markers of cardiotoxicity in adults undergoing cancer treatment.\n\nParticipants with breast cancer, hematologic malignancy, or multiple myeloma will receive usual care plus two wearable patch monitors: mobile cardiac telemetry using the BodyGuardian Mini Plus ambulatory ECG monitor and an investigational wearable cardiac monitor that records heart sounds. The study will assess arrhythmias detected by mobile cardiac telemetry and explore whether heart sounds are associated with echocardiographic findings and cardiac biomarkers.\n\nParticipants will wear the devices during cancer treatment, with monitoring periods at baseline and possible repeat monitoring at 6-month and 12-month study visits.",[317,26,318,319,320,321],"Cardiotoxicity","Cardiac Arrhythmia","Left Ventricular Dysfunction","Breast Cancer","Multiple Myeloma",[323,324,325,326,327,328],"MCT-WAVE","Mobile cardiac telemetry","Wearable cardiac monitor","Cardio-oncology","Ventricular arrhythmia","Breast cancer",{"date":29,"type":32},{"date":331,"type":20},"2026-09-01",{"date":333,"type":20},"2028-09-01",{"name":335,"class":39},"University of Minnesota",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":40},"100652587","indirect-calorimetry-guided-parenteral-nutrition-prescribing-in-oncology-patients-100652587","NCT07776704","Indirect Calorimetry-Guided Parenteral Nutrition Prescribing in Oncology Patients","Comparing Measured Resting Energy Expenditure to Weight-Based Equations for Parenteral Nutrition Prescribing in Oncology Patients: A Randomized Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diagnosis of cancer\n* Requirement for PN ≥1 week\n* Ability to provide informed consent\n* English-speaking\n\nExclusion Criteria:\n\n* Hospice enrollment\n* Mechanical ventilation\n* Chest tube or drain\n* Continuous renal replacement therapy\n* Supplemental oxygen",{"count":131,"type":20},[23],"This study compares two methods of prescribing parenteral nutrition (PN) in adults with cancer who are unable to meet nutritional needs by oral or enteral intake.",[347,26],"Malnutitrion",[349,350,351,352,113],"Parenteral Nutrition","Indirect Calorimetry","Oncology","Resting Energy Expenditure",{"date":29,"type":32},{"date":355,"type":32},"2025-08-21",{"date":357,"type":20},"2029-01",{"name":359,"class":39},"Fox Chase Cancer Center",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":21,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":379},"100574232","the-ecog-acrin-support-trial-multilevel-intervention-to-improve-diverse-enrollment-in-cancer-clinical-trials-100574232","NCT06756607","The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials","Inclusion Criteria:\n\nParticipant must be ≥ 18 years of age. Participant must self-identify as Black and\u002For Latino. Participant must be an oncology patient at a participating NCORP. Participant must be eligible to participate in an ECOG-ACRIN clinical trial. Participant must have the ability to understand and the willingness to sign a e-consent document.\n\nParticipant must be receiving care at a participating NCORP affiliated community oncology site.\n\nParticipant must be English or Spanish speaking to be eligible. Participant must have access to a landline, smartphone, computer, or tablet.\n\nExclusion Criteria:\n\n\\-",{"count":367,"type":20},500,[23],"The purpose of this study is to conduct a Hybrid Type 1 cluster-randomized, roll-out effectiveness-implementation trial in NCORP community oncology practice sites (N= 500 Black and Latino cancer patients) to evaluate the effectiveness of the EA SUPPORT intervention combining CT navigators and CT research literacy tools in improving Black and Latino patient referral and accrual to NCI-supported CTs (primary outcomes) and participant and provider awareness and knowledge of CTs (secondary outcomes) while assessing implementation factors. Also, with the CUSP2CT data, Evaluation, and Coordinating Center, conduct final site evaluation and disseminate the SUPPORT intervention to NCORP community oncology sites, research bases, and affiliated trial networks.",[26],{"date":193,"type":32},{"date":373,"type":32},"2025-04-25",{"date":375,"type":20},"2028-03-01",{"name":377,"class":378},"Eastern Cooperative Oncology Group","NETWORK",67,{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":17,"minAge":386,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":21,"phases":389,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":40},"100484445","phase-1-a-phase-iii-study-of-zotiraciclib-for-recurrent-malignant-gliomas-with-isocitrate-dehydrogenase-1-or-2-idh1-or-idh2-mutations-100484445","NCT05588141","A Phase I\u002FII Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","* INCLUSION CRITERIA:\n* Participants must have diffuse glioma, WHO grades 2-4, histologically confirmed by Laboratory of Pathology, NCI.\n* IDH1 or IDH2 mutation status confirmed by TruSight(TM) Oncology 500 performed in LP, NCI or prior documentation of IDH1 or IDH2 mutation status\n* Participants must have received prior treatment (e.g., radiation, conventional chemotherapy, or vorasidenib) prior to disease progression.\n* Participants must have recurrent disease, proven histologically or by imaging studies\n* Participants who have undergone prior surgical resection are eligible for enrollment to cohorts 1-4.\n* Age \\>15 years\n* Karnofsky \\>70%\n* Participants must have adequate organ and marrow function as defined below:\n\n  * leukocytes \\>=3,000\u002Fmicroliter\n  * absolute neutrophil count (ANC) \\>=1,500\u002Fmicroliter\n  * platelets \\>100,000\u002Fmicroliter\n  * total bilirubin \\\u003C=2x ULN (ULN 1.3 mg\u002Fdl) except for participants with Gilbert Syndrome\n  * AST \\\u003C 3x ULN (ULN 34U\u002FL)\n  * ALT \\\u003C 3x ULN (ULN 55U\u002FL)\n  * serum creatinine \\\u003C 1.5 mg\u002FdL\n  * calculated creatinine clearance by CKD-EPI equation \\> 60 cc\u002Fmin\n* Participants must have recovered from the adverse effects of prior therapy to grade 2 or less (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0)\n* Individuals of child-bearing potential (IOCBP) and men must agree to use highly effective contraception (hormonal, intrauterine device (IUD), abstinence, tube ligation, partner has had a previous vasectomy) at the study entry, for the duration of study treatment, and up to 3 months after the last dose of zotiraciclib\n* Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 3 months after study treatment discontinuation\n* Participants must be scheduled for brain tumor biopsy or surgical resection at NIH (Cohort 5 only)\n* The ability of a participant, parent or legal guardian of minor participant to understand and the willingness to sign a written informed consent document. No Legally Authorized Representative can provide initial consent.\n\nEXCLUSION CRITERIA:\n\n* More than one disease relapse in those with initial diagnosis of WHO grade 3-4, or more than two disease relapses in those with initial diagnosis of WHO grade 2 for Phase II. For Phase I enrollment, there are no limits on the number of prior recurrences.\n* Prior therapy with:\n\n  * any investigational agent (including IDH mutant inhibitor) and\u002For standard of care cytotoxic therapy within 28 days prior to treatment initiation\n  * vincristine within 14 days prior to treatment initiation\n  * nitrosoureas within 42 days prior to treatment initiation\n  * procarbazine within 21 days prior to treatment initiation\n  * non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, within 7 days prior to treatment initiation\n  * surgery within 14 days prior to treatment initiation\n  * radiation therapy within 30 days prior to treatment initiation\n  * bevacizumab for tumor treatment. Note: participants who received bevacizumab for symptom management, including but not limited to cerebral edema, or pseudo progression can be enrolled\n* Prolonged QTc \\>470ms as calculated by correction formula on screening electrocardiogram (ECG) (QTCf can be used; QTCb can be used for participants with sinus bradycardia)\n* Prior invasive malignancies within the past 3 years prior to study treatment initiation (with the exception of non-melanoma skin cancers, carcinoma in situ of the cervix, melanoma in situ, or any localized cancer for whom the systemic standard of care therapy is not required)\n* History of allergic reactions attributed to compounds of similar chemical composition to zotiraciclib, such as flavopiridol\n* Pregnancy (confirmed with beta-HCG serum or urine pregnancy test performed at screening)\n* Uncontrolled intercurrent illness or social situations that would limit compliance with study requirements\n* Uncontrolled primary diabetes mellitus","15 Years",{"count":388,"type":20},96,[80,390],"PHASE2","Background:\n\nDiffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.\n\nObjective:\n\nTo see if a study drug (zotiraciclib) is effective in people with recurrent diffuse gliomas who have IDH1 or IDH2 mutations.\n\nEligibility:\n\nPeople aged 15 years and older with diffuse gliomas that returned after treatment. They must also have mutations in the IDH1 or IDH2 genes.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood and urine tests. They will have tests of their heart function. They will have an MRI of their brain. A new biopsy may be needed if previous results are not available.\n\nZotiraciclib is a capsule taken by mouth with a glass of water. Participants will take the drug at home on days 1, 4, 8, 11, 15, and 18 of a 28-day cycle. They may also be given medications to prevent side effects of the study drug. The schedule for taking the study drug may vary for participants who will undergo surgery.\n\nParticipants will be given a medication diary for each cycle. They will write down the date and time of each dose of the study drug.\n\nParticipants will visit the clinic about once a month. They will have a physical exam, blood tests, and tests to evaluate their heart function. An MRI of the brain will be repeated every 8 weeks.\n\nParticipants may remain in the study for up to 18 cycles (1.5 years).",[393,26],"Brain Tumor",[393,395,396,397],"Glioma","Idh Mutation","Recurrent Disease",{"date":193,"type":32},{"date":400,"type":32},"2023-05-16",{"date":402,"type":20},"2032-08-02",{"name":170,"class":171},{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":4,"leadSponsor":422,"locationsCount":40},"100060089","evaluation-of-late-effects-and-natural-history-of-disease-in-patients-treated-with-radiotherapy-100060089","NCT00026650","Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy","* INCLUSION CRITERIA:\n\nROB investigator deems that it is in the best interests of the participant and the NCI\u002FROB for the participant to be seen in follow-up in the ROB clinic.\n\nParticipant is able to provide informed consent.\n\nParticipant must have a primary physician in the community to whom records and appropriate follow-up management can be given. Social services will be enlisted for any participants who lack health insurance, etc.\n\nParticipants who have received radiotherapy.\n\nAge greater than or equal to 18 years of age\n\nEXCLUSION CRITERIA:\n\nParticipants who are on an interventional research protocol at NIH at the time of enrollment.","120 Years",{"count":412,"type":20},700,"BACKGROUND\n\n* This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our participants, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols.\n* It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PDT, radiation modifiers,\n\nintraoperative radiotherapy, etc.\n\nOBJECTIVE\n\n-The primary objective of this protocol is to assess the late effects of treatment and the natural history of disease through collection of data from any standard procedures performed as part of follow up care on participants previously treated with radiotherapy.\n\nELIGIBILITY\n\n-Participants who received radiation therapy.\n\nDESIGN\n\n* This is a natural history protocol in which long-term follow up data will be collected from participants who received radiation therapy.\n* It will be made clear to participants in the consent form, that data collected during their follow-up may be used anonymously for publications concerning the natural history of disease processes and long-term effects of treatment.",[26],[416,417,26,163],"Late Effects","Radiation Therapy","2026-08-15",{"date":193,"type":32},{"date":421,"type":32},"2000-02-14",{"name":170,"class":171},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":430,"minAge":431,"maxAge":432,"enrollmentInfo":433,"targetDuration":4,"studyType":21,"phases":434,"briefSummary":435,"conditions":436,"keywords":437,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":40},"100649765","exert-bc-cardio-cardio-or-conditioning-training-with-breast-cancer-100649765","NCT07739563","EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer","EXERT-BC Cardio: Randomized Study of EXErcise Regimens After Treatment for Breast Cancer Utilizing Cardio or Conditioning Training","Inclusion Criteria:\n\n1. Age 20-89 years\n2. Women prescribed exercise as a SOC\n3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast\n4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.\n5. Women with \\> 3 months of resistance training experience under expert guidance by a CSCS\n6. Must be able to read and understand English and consent for themselves.\n\nExclusion Criteria:\n\n1. Any current treatment with cytotoxic chemotherapy for breast cancer\n2. Inability to safely engage in group sessions of resistance training as deemed by study PI\n3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training\n4. Beta blocker or GLP-1 inhibitor medications\n5. Pregnant women\n6. Males","FEMALE","20 Years","89 Years",{"count":211,"type":20},[23],"In this study, the investigators hypothesize that observed intense resistance training with conditioning elicits similar changes in body composition, muscle mass, and blood pressure as that with cardiovascular training (or cardio) for women treated with breast cancer.",[26,320],[438],"Exercise","2026-08-14",{"date":298,"type":32},{"date":442,"type":32},"2026-07-27",{"date":66,"type":20},{"name":445,"class":39},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":49,"sex":17,"minAge":453,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":21,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":40},"100592458","revealing-information-genuinely--honestly-across-time---communication-preferences-visit-100592458","NCT06993688","Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit","Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit (RIGHTimeCPV) Pilot","Inclusion Criteria: Patients\n\n* Aged 12-25 years diagnosed with poor prognosis cancer (high risk or otherwise difficult to treat cancers), as defined by a pediatric oncologist estimating odds of overall survival as 50% or less\n* Anticipated by a pediatric oncologist to have one or more disease re-evaluation timepoints over the next six months\n* Not anticipated by a pediatric oncologist to approach end of life in the next three months\n\nInclusion Criteria: Parents\u002FCaregivers\n\n* Aged 18 years or older and\u002For legally emancipated\n* Parent or other self-identified caregiver of a patient of any age with poor prognosis cancer (as defined above)\n\nInclusion Criteria: Oncologists\n\n* Pediatric oncologists who treat eligible patients\u002Fcaregivers at the study site, St. Jude Children's Research Hospital (SJCRH) or its included affiliates:\n\n  * Peoria, IL: The Jim and Trudy Maloof St. Jude Midwest Affiliate Clinic\n  * Charlotte, NC: Novant Health Hemby Children's Hospital\n  * Shreveport, LA: Ochsner LSU Health-Feist-Weiller Cancer Center\n\nInclusion Criteria: Communication Preferences Companions (CPCs)\n\n* Multidisciplinary clinicians from a participant's psychosocial or nursing care team, identified by that participant to serve as their 'communication preferences companion' (CPC) during the pilot\n* Provides clinical care to pediatric cancer patients under the auspices of psychology, social work, spiritual care, child life, cultural navigation, quality of life\u002Fpalliative care, or nursing\n\nExclusion Criteria:\n\n* Does not meet the stated inclusion criteria","12 Years",{"count":455,"type":20},85,[23],"The purpose of this research study is to obtain insights and feedback from patients and parents about a new approach to support conversations about how cancer may affect one's future life and quality of life (i.e., prognostic communication). This study involves creating a personalized approach to discussing prognosis.\n\nPrimary Objectives\n\n* To evaluate the feasibility of implementing the RIGHTimeCPV intervention among pediatric oncology patients, caregivers, and clinicians (referred to herein as \"shareholders\").\n* To assess the acceptability of the intervention across the shareholder groups.\n\nSecondary Objectives\n\n* To explore the potential impact of the RIGHTimeCPV intervention on communication quality, concordance in prognostic understanding, and therapeutic alliance between patients\u002Ffamilies and multidisciplinary clinicians.\n* To explore whether the practice of eliciting, sharing, and honoring individualized communication preferences is sustained by clinicians after participation in the RIGHTimeCPV intervention.",[26,459],"Communication",[461,26,462,463,464,465,466],"Prognostic Communication","Poor Prognosis","Participants 12-25 years of age","Caregivers","Pediatric oncologists","Communication Preferences Companions",{"date":298,"type":32},{"date":469,"type":32},"2025-06-16",{"date":471,"type":20},"2027-11-01",{"name":473,"class":39},"St. Jude Children's Research Hospital",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":430,"minAge":386,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":484,"briefSummary":485,"conditions":486,"keywords":488,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":501},"100586418","phase-2-acupuncture-for-people-experiencing-period-loss-due-to-chemotherapy-100586418","NCT06915116","Acupuncture for People Experiencing Period Loss Due to Chemotherapy","Acupuncture for Adolescent and Young Adult Cancer Patients: (AcuAYA)","Inclusion Criteria:\n\n* English speaking woman between the ages of 15 and 40\n* History of stage I, II, or III cancer OR stage IV or unstaged hematologic malignancy (e.g. lymphoma, leukemia, myeloma) that is stable, as assessed by care team\n* Premenopausal status with regular menstruation at the time of diagnosis by patient report\n* Completed cytotoxic chemotherapy within the past year\n* Premenopausal status with regular menstruation at the time of diagnosis by patient report for females ages 18 or older\n* Report cessation of menses during or after chemotherapy and have not experienced menses recovery at the time of enrollment.\n* Have reached menarche prior to therapy or during therapy for females between 15 and 17 years old\n* Patient meets at least one of the following:\n* Reports cessation of menses during or after chemotherapy and have not experienced menses recovery at the time of enrollment and has been without menses for at least 3 months 64 following the completion of cytotoxic chemotherapy; OR\n* Is receiving ovarian suppression therapy (e.g., leuprolide \\[Lupron\\] or goserelin \\[Zoladex\\]) or hormonal contraceptive drugs, regardless of menstrual status, and report persistent (≥3 months), moderate-to- severe menopause-related symptoms, defined as a score of ≥4 on a 0-10 scale for at least one MENQOL item during eligibility screening.\n* Willing to adhere to all study-related procedures, including randomization to one of the two possible arms: acupuncture and WLC\n\nExclusion Criteria:\n\n* Had been pregnant or lactating within 3 months prior to enrollment\n* History of hysterectomy or bilateral oophorectomy\n* Ongoing or planned radiation or surgery within 4 months from randomization\n* Use of acupuncture for menses recovery within 3 months of enrollment\n* Had been or will be receiving ovarian suppression medicine, such as leuprolide (Lupron) and goserelin (Zoladex), or hormonal contraception drugs within 3 months of enrollment or during the study period","40 Years",{"count":483,"type":20},60,[390],"The purpose of this study is to find out whether it is practical (feasible) to use acupuncture to treat period loss (amenorrhea) caused by chemotherapy treatment in people with cancer. The researchers will look at how many participants enroll and complete the study. The researchers will also study how treatment with acupuncture affects the amount of time for the menstrual cycle to return and symptoms and quality of life related to amenorrhea.",[26,487],"Period Problem",[489,490,491,492,493],"Acupuncture","Stage I cancer","Stage II cancer","Stage III cancer","Period Loss Due to Chemotherapy",{"date":298,"type":32},{"date":496,"type":32},"2025-03-31",{"date":498,"type":20},"2027-03-31",{"name":500,"class":39},"Memorial Sloan Kettering Cancer Center",7,{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":510,"conditions":511,"keywords":512,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":523},"100468216","met-non-small-cell-cancer-registry-moment-100468216","NCT05376891","Met Non Small Cell Cancer Registry (MOMENT)","Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)","Inclusion Criteria:\n\n* Participants who signed ICF\n* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)\n* Participants who are starting or are already being treated with systemic therapy\n\nExclusion Criteria:\n\n* Participants who are enrolled in a clinical trial",{"count":412,"type":20},"The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.\n\nThe registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.",[26],[513,514],"Disease Registry","METex14 Skipping Alterations",{"date":298,"type":32},{"date":517,"type":32},"2022-10-04",{"date":519,"type":20},"2028-04-28",{"name":521,"class":522},"EMD Serono Research & Development Institute, Inc.","INDUSTRY",79,{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":532,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":21,"phases":534,"briefSummary":535,"conditions":536,"keywords":554,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":580},"100626796","phase-2-determine-trial-treatment-arm-07-dabrafenib-in-combination-with-trametinib-in-adult-paediatric-and-teenageyoung-adult-patients-with-braf-v600-mutation-positive-cancers-100626796","NCT07440290","DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With BRAF V600 Mutation-Positive Cancers.","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and TYA Patients With BRAF V600 Mutation-Positive Cancers.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 07 (DABRAFENIB AND TRAMETINIB) OUTLINED BELOW\\* \\*When dabrafenib- and trametinib-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the dabrafenib- and trametinib-specific criteria will take precedence.\n\nInclusion criteria:\n\nA. Confirmed diagnosis of a malignancy harbouring an oncogenic alteration in BRAF V600, including Langerhans cell histiocytosis, using an analytically validated next-generation sequencing method.\n\nB. Patients ≥1 year old and ≥8 kg in body weight.\n\nC. Women of childbearing potential are eligible provided that they meet the following criteria:\n\n• Have a negative serum or urine pregnancy test before enrolment and;\n\n• Agree to use one form of a non-hormonal highly effective contraception method (a method that can achieve a failure rate of \\\u003C1% when used consistently and correctly; the requirement for non-hormonal method is because dabrafenib may decrease the efficacy of oral or any systemic hormonal contraceptives), such as: i. intrauterine device (IUD), ii. bilateral tubal occlusion, bilateral tubal ligation (at least six weeks before taking trial treatment), iii. vasectomised partner, iv. total sexual abstinence. Effective from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).\n\nPatients who are breastfeeding must be willing to discontinue breastfeeding from the start of treatment, throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).\n\nD. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks after the last administration of dabrafenib and 16 weeks after the last administration of trametinib (whichever is later):\n\n* Agree to take measures not to father children by using a barrier method of contraception (male condom plus spermicide) or to sexual abstinence.\n* Non-vasectomised male partners with partners who are women of childbearing potential should also be advised of the benefit for their partner of using a highly effective method of contraception, such as:\n\n  i. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal or transdermal\\]), ii. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), iii. IUD, iv. intrauterine hormone-releasing system (IUS), v. bilateral tubal occlusion, vi. total sexual abstinence.\n* Male patients with pregnant or breastfeeding partners must be advised to use barrier method contraception (male condom) to prevent drug exposure of the foetus or neonate, even if vasectomised.\n* Male patients must refrain from donating sperm for the same period.\n\nE. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nF. Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility\n\nExclusion criteria:\n\nA. Diagnosis of one of the following BRAF V600E mutation-positive cancers:\n\n* Colorectal cancer in adult (≥18 years) patients;\n* Unresectable or metastatic melanoma in adult (≥18 years) patients;\n* Advanced non-small cell lung cancer in adult (≥18 years) patients;\n* Gliomas harbouring a BRAF V600E mutation in paediatric (1 to \\\u003C16 years) or TYA (16 to \\\u003C18 years) patients.\n\nB. Previous treatment with dabrafenib and trametinib in combination (or other BRAF and MEK inhibitors in combination) for the current indication.\n\nC. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for two weeks following their last dose of dabrafenib or 16 weeks following their last dose of trametinib, whichever is later.\n\nD. Known hypersensitivity to dabrafenib or trametinib or any of the excipients. See the current relevant SmPCs (UK) for the full lists.\n\nE. Patients with a history of retinal vein occlusion.\n\nF. Any impairment of gastrointestinal (GI) function of uncontrolled GI disease that may significantly alter the administration or absorption of dabrafenib and\u002For trametinib (e.g. history of diverticulitis, metastases to the GI tract, uncontrolled Crohn's disease, uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome or short gut syndrome).\n\nG. Clinically significant cardiac or cerebrovascular disease as defined by:\n\n* Unstable angina within three months prior to screening;\n* Myocardial infarction within three months prior to screening;\n* History of documented congestive heart failure (New York Heart Association functional classification III\u002FIV) etc.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attack \\[TIA\\]) within three months prior to screening.\n\n• Patients with primary central nervous system (CNS) tumours may be considered unless intratumoural bleeding has occurred within two weeks prior to the first dose of dabrafenib and trametinib, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nH. Patients who were administered a live, attenuated vaccine within 28 days prior to initiation of treatment, or anticipation of need for such a vaccine during investigational medicinal product (IMP) treatment or within six months after the final dose of dabrafenib and trametinib.\n\nI. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of dabrafenib and trametinib including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided that each of the following conditions are met:\n\n* CD4 count ≥350\u002FµL;\n* Undetectable viral load;\n* Receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* No HIV\u002Facquired immune deficiency syndrome associated opportunistic infection in the last 12 months.\n\nJ. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial (including absorption of oral medications) that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.","1 Year",{"count":19,"type":20},[390,268],"This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600.\n\nInvestigators now wish to find out if they will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[537,538,539,540,541,542,543,544,26,545,546,547,548,549,550,395,321,551,552,553],"Haematological Malignancy","Malignant Neoplasm","Lymphoproliferative Disorders","Neoplasms by Histologic Type","Neoplasms by Site","Gastrointestinal Cancer","Non-Melanoma Skin Cancer (NMSC)","Langerhans Cell Histiocytosis (LCH)","Erdheim-Chester Disease","Thyroid Carcinoma, Papillary","Ovarian Neoplasms","Colorectal Neoplasms","Laryngeal Neoplasms","Carcinoma, Non-Small Cell-Lung","Thyroid Carcinoma, Anaplastic","Solid Tumour","Pancreatic Diseases",[555,556,26,557,558,559,560,561,562,563,541,564,565,566,567,568,569,570,571],"Adult","Antineoplastic Agents","Child","Dabrafenib","Malignancy","Malignant Neoplasms","Molecular Targeted Therapy","Mutation","Neoplasms by Histologic Site","Paediatric","Precision Medicine","Proto-Oncogene Proteins B-raf","Protein Kinase Inhibitors","Rare","Trametinib","Tumour-Agnostic","Young adult","2026-08-13",{"date":298,"type":32},{"date":575,"type":32},"2026-04-01",{"date":577,"type":20},"2029-10",{"name":579,"class":39},"Cancer Research UK",27,{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":585,"acronym":4,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":21,"phases":589,"briefSummary":590,"conditions":591,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":40},"100547522","psycho-spiritual-management-for-patients-with-advanced-cancer-and-their-family-caregivers-100547522","NCT06409065","Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers","Inclusion Criteria:\n\n* Be diagnosed with a metastatic (stage IV) breast, thoracic, gastrointestinal, gynecological, or genitourinary cancer\n* Be without disease progression for at least 3 months based on surveillance CT imaging\n* Have an ECOG performance status of ≤2\n* Have a family caregiver willing to participate\n\nBoth patient and caregiver must meet all the following criteria:\n\n* Be ≥18 years old\n* Be able to read and speak English or Spanish.\n* Be able to provide informed consent\n\nAdditionally, either the patient and\u002For caregiver must:\n\n• Have a NCCN Distress Thermometer score of ≥4\n\nExclusion Criteria:\n\nA patient who meets the following criteria will be excluded from participation in this study:\n\n• Have cognitive deficits that would impede the completion of self-report instruments as deemed by their attending oncologist\n\n3.3 Vulnerable Populations This study is designed for individuals who are at least 18 years of age, and there is no upper age limit. Children under the age of 18 will not be included. First and foremost, it is unlikely that a minor is diagnosed with a metastatic solid tumor. It is also unlikely that a minor serves as the primary family caregiver of a patient with cancer. Additionally, the intervention is designed for adults, and the assessment tools are not validated for minors. While pregnant caregivers (self-identified) are study eligible, we will also exclude pregnant patients (medical notes).\n\n3.4 Recruitment\u002FScreening Process Eligible study participants (i.e. cancer patients) will be identified using the electronic clinic appointment systems on their tumor characteristics (i.e. cancer type and stage) and date of birth (i.e. minimum 18 years old). Potential patients and caregivers will be approached during patients' appointment at an outpatient oncology appointment, screened for eligibility, and consented. Since this is a family-based intervention, it is possible that caregivers will not be present during the patients' clinic visits. If so, patients will be asked for permission to contact the caregiver via phone to obtain consent.",{"count":588,"type":20},400,[23],"The goal of this behavioral research study is to learn about the effects of two different supportive care programs on patients' and their family caregivers' psychological wellbeing and overall quality of life.",[26],{"date":439,"type":32},{"date":594,"type":32},"2024-01-09",{"date":596,"type":20},"2028-08-31",{"name":305,"class":39},{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":4,"eligibilityCriteria":604,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":605,"targetDuration":4,"studyType":21,"phases":607,"briefSummary":608,"conditions":609,"keywords":624,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":633,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":640},"100509886","phase-1-fog-001-in-locally-advanced-or-metastatic-solid-tumors-100509886","NCT05919264","FOG-001 in Locally Advanced or Metastatic Solid Tumors","A Phase 1\u002F2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and marrow function.\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1a and Part 1g):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic solid tumor that is non-MSI-H or non-dMMR colorectal cancer (CRC) or any other solid tumor with documented WNT- pathway activating mutations (WPAMs).\n\nAdditional Inclusion Criteria for Dose Escalation Cohorts (Part 1b):\n\n* Diagnosis of treatment-refractory advanced\u002Fmetastatic non-MSI-H or non-dMMR CRC.\n* At least one lesion that is suitable for a core needle biopsy.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1c and Part 2c):\n\n* Histologically, cytologically, or radiographically confirmed HCC with a documented WPAM (by local ctDNA or tumor NGS testing) in APC or CTNNB1\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1d, Part 1h, and Part 2d):\n\n* Desmoid tumor (aggressive fibromatosis)\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-1 and Part 2f-1) FOG-001 + FOLFOX + Bevacizumab:\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n* One dose of mFOLFOX6 with or without bevacizumab in the unresectable or metastatic setting prior to enrollment is allowed.\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-2 and Part 2f-2): FOG-001 + Nivolumab\n\n* Non-MSI-H or non-dMMR (by local testing) CRC with or without liver metastases.\n* MSI-H CRC or solid tumors that are WPAM and resistant to a-PD-1\u002FPD-L1\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible\n\nAdditional Inclusion Criteria for Dose Escalation and Dose Expansion Cohorts (Part 1f-3 and Part 2f-3): FOG-001 + Trifluridine\u002FTipiracil + Bevacizumab\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n* Participants with tumors known to be negative for APC LoF mutations or CTNNB1 GoF mutations (per NGS tests) are not eligible.\n\nMonotherapy Dose Optimization (Part 1i): FAP\n\n* Diagnosis of phenotypic classical FAP with a documented APC mutation\n* Post-colectomy \\>6 months prior to first dose of study drug administration with measurable duodenal polyp burden\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2a):\n\n* Diagnosis of locally advanced or metastatic non-MSI-H or non-dMMR (by local testing) CRC\n\nAdditional Inclusion Criteria for Dose Expansion Cohort (Part 2b):\n\n* Diagnosis of advanced or metastatic solid tumors with a documented WPAM (by local testing) or equivalent evidence\n\nExclusion Criteria:\n\n* Known history of bone metastasis. Bone metastasis are allowed for patients with mCRPC. For participants with FAP, osteomas are allowed.\n* Evidence of vertebral compression fracture or non-traumatic bone fracture within the past 12 months and who are not receiving antiresorptive therapy.\n* Osteoporosis, which is defined as a T-score of ≤-2.5 at the lumbar spine (L1 - L4), left (or right) femoral neck or left (or right) total hip as determined by DXA scan.\n* Uncontrolled inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease)\n* Unstable\u002Finadequate cardiac function.\n* Has known meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases.\n* Pregnant, lactating, or planning to become pregnant.\n* Complete colectomy within 6 months of the first dose of study drug administration.",{"count":606,"type":20},619,[80,390],"The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).",[26,610,611,612,613,614,615,616,617,618,619,620,621,622,623],"Colorectal Cancer","Solid Tumor","Locally Advanced Solid Tumor","Metastatic Cancer","WNT Pathway","HCC","Desmoid","Microsatellite Stable Colorectal Cancer","Metastatic Castration-resistant Prostate Cancer","Familial Adenomatous Polyposis (FAP)","Endometrial Carcinoma","Prostate Cancer","Microsatellite Instability-High Colorectal Cancer","Adamantinomatous Craniopharyngioma",[26,611,612,613,625,626,627,616,628,629,630,631,632],"WNT Pathway Activating Mutation (WPAM)","Colorectal Cancer (CRC)","Microsatellite Stable (MSS)","Hepatocellular Carcinoma (HCC)","Adenomatous Polyposis Coli (APC)","β-catenin","Beta-catenin","CTNNB1",{"date":298,"type":32},{"date":635,"type":32},"2023-05-23",{"date":637,"type":20},"2027-08-31",{"name":639,"class":522},"Parabilis Medicines, Inc.",33,{"id":642,"slug":643,"hasResults":12,"nctId":644,"briefTitle":645,"officialTitle":645,"acronym":4,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":649,"conditions":650,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":655,"locationsCount":40},"100508773","development-of-brief-positive-affect-treatment-pat-for-caregivers-of-patients-with-advanced-cancer-100508773","NCT05904782","Development of Brief Positive Affect Treatment (PAT) for Caregivers of Patients With Advanced Cancer","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Males and female adults ≥18 years\n* Able to read and speak English\n* Caregiver of a patient diagnosed with stage IV solid malignancy, with whom they have been residing for \\>6 months\n* Access to necessary resources for participating in a technology-based intervention (i.e., telephone, internet access)\n\nExclusion Criteria:\n\n* Current participation in consistent (self-defined) psychotherapy\n* Caregivers who are considered part of a vulnerable population (i.e. cognitively impaired (self-reported or patient-reported), pregnant, military personnel) will not be eligible.",{"count":648,"type":20},150,"To learn more about the experience and wellbeing of people who provide care for cancer patients.",[26],{"date":439,"type":32},{"date":653,"type":32},"2025-08-29",{"date":471,"type":20},{"name":305,"class":39},{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":661,"acronym":662,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":664,"targetDuration":532,"studyType":53,"phases":4,"briefSummary":666,"conditions":667,"keywords":669,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":674,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":40},"100371353","attribution-of-toxicities-due-to-radiotherapy-and-immuno-biological-therapies-100371353","NCT04115267","Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies","Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry","AtTRIBut","Inclusion Criteria:\n\n* Consent to be part of the AtTRIBut registry\n* Prior histological diagnosis of primary cancer.\n* If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis\n* Age\\> 18 years\n* Receiving a molecular therapy\n* Indicated to receive radiotherapy\n* Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques.\n\nExclusion Criteria:\n\n• Refusal or inability to receive radiotherapy",{"count":665,"type":20},3600,"Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.",[26,668],"Radiotherapy Side Effect",[670,671,672,673,26],"Combined effect","Registry","Side effects","Patient reported outcome",{"date":439,"type":32},{"date":676,"type":32},"2019-09-13",{"date":678,"type":20},"2030-09-30",{"name":680,"class":39},"Centre hospitalier de l'Université de Montréal (CHUM)"]